CULVER CITY, Calif. ’ ImmunityBio, Inc. (NASDAQ: IBRX) has made a significant leap in the accessibility of its cancer treatment, ANKTIVA (nogapendekin alfa inbakicept-pmln), securing coverage from more than a dozen insurance plans. This move represents over 100 million lives covered just months following the drug’s FDA approval, marking an important milestone for patients seeking alternative therapies for their conditions.
The company announced this development as it continues to push for broad market access for ANKTIVA, focusing on both commercial and government insurance programs. This strategy is pivotal for ensuring that patients diagnosed with bladder cancer have the necessary support to receive the innovative treatment.
Dr. Patrick Soon-Shiong, Executive Chairman of ImmunityBio, expressed optimism about the progress made in expanding the reach of ANKTIVA, affirming that the company’s commercial team has successfully targeted key market access initiatives. “We are committed to making our therapies accessible to as many patients as possible. This coverage expansion is a vital step in our mission, he stated.
In addition to bolstering its domestic market presence, ImmunityBio has plans to extend its bladder cancer program internationally. The company has identified potential opportunities for expansion in the European Union and India, regions with significant patient populations and an increasing need for advanced cancer therapies. ImmunityBio aims to tailor its strategies to meet the diverse healthcare landscapes of these regions, with the intent of providing comprehensive support to oncological patients.
As ImmunityBio continues to navigate the regulatory and market landscapes, the company remains focused on advancing its portfolio of immunotherapies. With growing optimism surrounding ANKTIVA’s potential and broader accessibility, the fight against bladder cancer takes a promising turn.
This comprehensive approach to market access, coupled with international expansion plans, positions ImmunityBio at the forefront of innovation in cancer treatment, offering hope to patients worldwide.
With more advancements on the horizon, the life sciences community and patients alike will be watching closely as ImmunityBio charts the next steps in its journey.
Comments